Stock Track | Iovance Biotherapeutics Soars 22.44% Intraday on Positive Sarcoma Therapy Data and Better-Than-Expected Q4 Operating Income

Stock Track

Feb 24

Iovance Biotherapeutics, Inc. saw its stock price soar 22.44% during intraday trading on Tuesday.

The significant surge follows the company's announcement of positive early data from a pilot clinical trial of its tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for patients with advanced soft tissue sarcomas. The data showed a confirmed objective response rate of 50% in the first six evaluable patients, with the company noting a favorable safety profile consistent with lifileucel in other indications. Iovance plans to commence a registrational trial in the second quarter of 2026 and engage with the FDA on an accelerated approval pathway.

Concurrently, the company released its fourth-quarter financial results, reporting an operating loss of $73.46 million, which was better than the IBES estimate of a $77.4 million loss. Revenue for the quarter was $86.77 million, exceeding analyst expectations and driven by demand for its approved therapy, Amtagvi.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1135052795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135052795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135052795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135052795","market":"nz","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Soars 22.44% Intraday on Positive Sarcoma Therapy Data and Better-Than-Expected Q4 Operating Income","media":"Stock Track","content":"<p>Iovance Biotherapeutics, Inc. saw its stock price soar 22.44% during intraday trading on Tuesday.</p><p>The significant surge follows the company's announcement of positive early data from a pilot clinical trial of its tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for patients with advanced soft tissue sarcomas. The data showed a confirmed objective response rate of 50% in the first six evaluable patients, with the company noting a favorable safety profile consistent with lifileucel in other indications. Iovance plans to commence a registrational trial in the second quarter of 2026 and engage with the FDA on an accelerated approval pathway.</p><p>Concurrently, the company released its fourth-quarter financial results, reporting an operating loss of $73.46 million, which was better than the IBES estimate of a $77.4 million loss. Revenue for the quarter was $86.77 million, exceeding analyst expectations and driven by demand for its approved therapy, Amtagvi.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Soars 22.44% Intraday on Positive Sarcoma Therapy Data and Better-Than-Expected Q4 Operating Income</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Soars 22.44% Intraday on Positive Sarcoma Therapy Data and Better-Than-Expected Q4 Operating Income\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Iovance Biotherapeutics, Inc. saw its stock price soar 22.44% during intraday trading on Tuesday.</p><p>The significant surge follows the company's announcement of positive early data from a pilot clinical trial of its tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for patients with advanced soft tissue sarcomas. The data showed a confirmed objective response rate of 50% in the first six evaluable patients, with the company noting a favorable safety profile consistent with lifileucel in other indications. Iovance plans to commence a registrational trial in the second quarter of 2026 and engage with the FDA on an accelerated approval pathway.</p><p>Concurrently, the company released its fourth-quarter financial results, reporting an operating loss of $73.46 million, which was better than the IBES estimate of a $77.4 million loss. Revenue for the quarter was $86.77 million, exceeding analyst expectations and driven by demand for its approved therapy, Amtagvi.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1135052795","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135052795","pubTimestamp":1771944501,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Iovance Biotherapeutics, Inc. saw its stock price soar 22.44% during intraday trading on Tuesday.The significant surge follows the company's announcement of positive early data from a pilot clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"个股追踪|Iovance Biotherapeutics盘中大涨22.44%肉瘤疗法数据积极、Q4营业收入好于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Iovance Biotherapeutics, Inc. saw its stock price soar 22.44% during intraday trading on Tuesday.The significant surge follows the company's announcement of positive early data from a pilot clinical trial of its tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for patients with advanced soft tissue sarcomas. The data showed a confirmed objective response rate of 50% in the first six evaluable patients, with the company noting a favorable safety profile consistent with lifileucel in other indications. Iovance plans to commence a registrational trial in the second quarter of 2026 and engage with the FDA on an accelerated approval pathway.Concurrently, the company released its fourth-quarter financial results, reporting an operating loss of $73.46 million, which was better than the IBES estimate of a $77.4 million loss. Revenue for the quarter was $86.77 million, exceeding analyst expectations and driven by demand for its approved therapy, Amtagvi.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}